{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:11:24Z","timestamp":1779340284153,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin A (BoNT-A) is well established for the esthetic treatment of upper-face dynamic lines, and long-term adult studies suggest that repeated treatment may remain effective and acceptable over time in many patients. However, wrinkle efficacy and patient satisfaction do not by themselves determine whether repeated treatment remains acceptable in broader morphologic, dynamic\u2013expressive, and longitudinal terms. At the same time, the toxin\u2019s pharmacology entails finite presynaptic blockade followed by active synaptic and architectural recovery, and imaging, histological, and neurophysiological studies indicate that repeated chemodenervation cannot be assumed to be biologically neutral at the muscle level. The resulting problem is not whether BoNT-A works, but whether current outcome frameworks are sufficient to judge repeated-treatment compatibility in full. Here, structural tolerance is proposed as a provisional clinical lens for an underdescribed boundary: whether repeated-treatment compatibility is fully captured by wrinkle reduction and patient acceptability alone. The paper organizes this problem across morphologic, dynamic\u2013expressive, and longitudinal domains, outlines candidate warning signs, and develops a pragmatic tiered approach to assessment spanning routine care, structured clinical follow-up, and research-oriented evaluation. The aim is to support more complete longitudinal thinking in upper-face aesthetic BoNT-A, to clarify what current outcome frameworks remain unaddressed, and to identify priorities for future empirical study.<\/jats:p>","DOI":"10.3390\/toxins18050232","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:11:31Z","timestamp":1779196291000},"page":"232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Wrinkle Efficacy: Toward a Broader Assessment of Longitudinal Compatibility in Routine Upper-Face Aesthetic BoNT-A"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8139-9169","authenticated-orcid":false,"given":"Andrea Felice","family":"Armenti","sequence":"first","affiliation":[{"name":"LA VISION Training Institute, Via Magenta, 5, 00199 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/DSS.0000000000004719","article-title":"Long-term consecutive onabotulinumtoxinA injections for facial aesthetic treatment: A real-world study","volume":"51","author":"Marques","year":"2025","journal-title":"Dermatol. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1111\/j.1524-4725.2006.32327.x","article-title":"German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4103 treatments in 945 patients","volume":"33","author":"Rzany","year":"2007","journal-title":"Dermatol. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/DSS.0000000000000450","article-title":"Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study","volume":"41","author":"Kerscher","year":"2015","journal-title":"Dermatol. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.36849\/JDD.2020.5013","article-title":"Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study","volume":"19","author":"Fischer","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nassif, A.D., Boggio, R.F., Espicalsky, S., and Faria, G.E.L. (2022). High precision use of botulinum toxin type A (BoNT-A) in aesthetics based on muscle atrophy, is muscular architecture reprogramming a possibility? A systematic review of literature on muscle atrophy after BoNT-A injections. Toxins, 14.","DOI":"10.3390\/toxins14020081"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cnp.2023.05.005","article-title":"Keeping up appearances: Don\u2019t frown upon the effects of botulinum toxin injections in facial muscles","volume":"8","author":"Punga","year":"2023","journal-title":"Clin. Neurophysiol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Salari, M., Sharma, S., and Jog, M.S. (2018). Botulinum toxin induced atrophy: An uncharted territory. Toxins, 10.","DOI":"10.3390\/toxins10080313"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/dsu.12125","article-title":"Muscle atrophy beyond the clinical effect after a single dose of onabotulinumtoxinA injected in the procerus muscle: A study with magnetic resonance imaging","volume":"39","author":"Koerte","year":"2013","journal-title":"Dermatol. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/mds.22661","article-title":"Muscle Biopsy Substantiates Long-Term MRI Alterations One Year After a Single Dose of Botulinum Toxin Injected into the Lateral Gastrocnemius Muscle of Healthy Volunteers","volume":"24","author":"Schroeder","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70508","DOI":"10.1111\/jocd.70508","article-title":"A psychological guide to upper face botulinum toxin injections: Baseline emotional functions of facial expressions","volume":"24","author":"Hopf","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70264","DOI":"10.1111\/jocd.70264","article-title":"The face of emotion: Botulinum toxin, emotional anatomy, and mood modulation","volume":"24","author":"Vanaria","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19214","DOI":"10.1038\/s41598-023-45779-9","article-title":"High-resolution surface electromyographic activities of facial muscles during the six basic emotional expressions in healthy adults: A prospective observational study","volume":"13","author":"Trentzsch","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yi, K.-H., Wan, J., Song, J.K., and Cartier, H. (2025). The facial muscle chain concept in forehead line treatment. Aesthetic Plast. Surg., online ahead of print.","DOI":"10.1007\/s00266-025-05230-y"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Eilert, D.W., Hopf, A.G.M., Alfertshofer, M., Prinz, V., Friedrich, M., and Cajkovsky, M. (2026). Botulinum Toxin and Social Perception: Effects of Upper-Face Treatment on Facial Emotion Attribution. Aesthetic Surg. J., advance online publication.","DOI":"10.1093\/asj\/sjag037"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"NP1","DOI":"10.1093\/asj\/sjae204","article-title":"Evaluating the Impact of BoNT-A Injections on Facial Expressions: A Deep Learning Analysis","volume":"45","author":"Ugurlu","year":"2024","journal-title":"Aesthetic Surg. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40272-019-00344-8","article-title":"Botulinum toxin in the management of children with cerebral palsy","volume":"21","author":"Multani","year":"2019","journal-title":"Paediatr. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/dmcn.13988","article-title":"Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: A 6-month prospective cohort study","volume":"60","author":"Alexander","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"De Beukelaer, N., Weide, G., Huyghe, E., Vandekerckhove, I., Hanssen, B., Peeters, N., Uytterhoeven, J., Deschrevel, J., Maes, K., and Corvelyn, M. (2022). Reduced cross-sectional muscle growth six months after botulinum toxin type-A injection in children with spastic cerebral palsy. Toxins, 14.","DOI":"10.3390\/toxins14020139"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lambrechts, C., De Beukelaer, N., Weide, G., Huyghe, E., Vandekerckhove, I., Hanssen, B., Peeters, N., Uytterhoeven, J., Deschrevel, J., and Van Campenhout, A. (2025). Botulinum neurotoxin A-induced muscle morphology changes in children with cerebral palsy: A one-year follow-up study. Toxins, 17.","DOI":"10.3390\/toxins17070327"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/asj\/sjy205","article-title":"A 3D Morphometrical Evaluation of Brow Position After Standardized Botulinum Toxin A Treatment of the Forehead and Glabella","volume":"39","author":"Schlager","year":"2019","journal-title":"Aesthetic Surg. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/j.1468-3083.2010.03631.x","article-title":"International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)\u2013Part I: Upper facial wrinkles","volume":"24","author":"Ascher","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1524-4725.2011.02248.x","article-title":"Validated assessment scales for the upper face","volume":"38","author":"Flynn","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamadermatol.2016.0018","article-title":"Development and Psychometric Validation of the FACE-Q Skin, Lips, and Facial Rhytids Appearance Scales and Adverse Effects Checklists for Cosmetic Procedures","volume":"152","author":"Klassen","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Jagu\u015b, D., Paw\u0142owska, A., and Mlosek, R.K. (2025). Ultrasound Evaluation of Upper Facial Muscles to Guide Botulinum Toxin Application. Toxins, 17.","DOI":"10.3390\/toxins17120595"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e70415","DOI":"10.1111\/jep.70415","article-title":"From Local Interventions to Systemic Modulation in Expressive and Neuromuscular Medicine: A Conceptual Reframing of Clinical Action","volume":"32","author":"Armenti","year":"2026","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/SAP.0000000000002994","article-title":"Long-term Effects of Repeated Botulinum Toxin Injection in Cosmetic Therapeutics","volume":"88","author":"Crook","year":"2022","journal-title":"Ann. Plast. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/DSS.0000000000001883","article-title":"OnabotulinumtoxinA for Simultaneous Treatment of Upper Facial Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Study","volume":"46","author":"Rivkin","year":"2020","journal-title":"Dermatol. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/DSS.0000000000003211","article-title":"Progressive Improvement in Static Glabellar Lines After Repeated Treatment with DaxibotulinumtoxinA for Injection","volume":"47","author":"Glogau","year":"2021","journal-title":"Dermatol. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dsu.12404","article-title":"Long-term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results From a 36-Month, Multicenter, Open-Label Extension Study","volume":"40","author":"Schlessinger","year":"2014","journal-title":"Dermatol. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/asj\/sjv208","article-title":"Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect","volume":"36","author":"Durand","year":"2016","journal-title":"Aesthetic Surg. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1097\/01.DSS.0000452645.76270.88","article-title":"Fields of Muscular and Anhidrotic Effects of 2 Botulinum Toxin-A Commercial Preparations: A Prospective, Double-Blind, Randomized, Multicenter Study","volume":"41","author":"Hexsel","year":"2015","journal-title":"Dermatol. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/asj\/sjaf063","article-title":"Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction with the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial","volume":"45","author":"Gold","year":"2025","journal-title":"Aesthetic Surg. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ojz015","DOI":"10.1093\/asjof\/ojz015","article-title":"The Psychological Impacts of Upper Facial Lines: A Qualitative, Patient-Centered Study","volume":"1","author":"Dayan","year":"2019","journal-title":"Aesthetic Surg. J. Open Forum"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/5\/232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:45:33Z","timestamp":1779338733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/18\/5\/232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["toxins18050232"],"URL":"https:\/\/doi.org\/10.3390\/toxins18050232","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]}}}